BR100 Decreased By (-0.73%)
BR30 Decreased By (-0.77%)
KSE100 Decreased By (-0.49%)
KSE30 Decreased By (-0.47%)
BECO 5.77 Increased By ▲ 0.46 (8.66%)
BML 53.00 Increased By ▲ 1.42 (2.75%)
BOP 33.99 Increased By ▲ 0.03 (0.09%)
CNERGY 8.11 Decreased By ▼ -0.20 (-2.41%)
DCL 12.20 Increased By ▲ 0.40 (3.39%)
FCCL 52.83 Decreased By ▼ -0.17 (-0.32%)
FCSC 5.07 Increased By ▲ 0.12 (2.42%)
FFL 17.95 Decreased By ▼ -0.20 (-1.1%)
FNEL 1.29 Decreased By ▼ -0.03 (-2.27%)
HUMNL 10.88 Decreased By ▼ -0.12 (-1.09%)
KEL 8.02 Decreased By ▼ -0.12 (-1.47%)
KOSM 5.52 Decreased By ▼ -0.06 (-1.08%)
MLCF 86.51 Decreased By ▼ -1.37 (-1.56%)
NBP 185.16 Decreased By ▼ -2.53 (-1.35%)
PACE 10.58 Decreased By ▼ -0.23 (-2.13%)
PAEL 39.42 Decreased By ▼ -0.65 (-1.62%)
PIAHCLA 26.22 Decreased By ▼ -0.27 (-1.02%)
PIBTL 16.67 Decreased By ▼ -0.09 (-0.54%)
PPL 228.18 Decreased By ▼ -2.19 (-0.95%)
PRL 34.68 Decreased By ▼ -0.36 (-1.03%)
PTC 65.33 Increased By ▲ 0.82 (1.27%)
SEARL 90.13 Increased By ▲ 0.25 (0.28%)
SSGC 26.60 Decreased By ▼ -0.37 (-1.37%)
TELE 8.28 Decreased By ▼ -0.09 (-1.08%)
THCCL 58.50 Decreased By ▼ -0.58 (-0.98%)
TPLP 8.22 Increased By ▲ 0.04 (0.49%)
TREET 24.53 Decreased By ▼ -0.47 (-1.88%)
TRG 69.71 Decreased By ▼ -0.92 (-1.3%)
WAVES 9.94 Decreased By ▼ -0.07 (-0.7%)
WTL 1.28 Decreased By ▼ -0.01 (-0.78%)
By

BEIJING: Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday.

The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

It demanded that AstraZeneca China close loopholes in supervision of marketing activities, the NHSA added.

In a statement on Friday, the company said some employees in the southern city of Shenzhen had altered or participated in altering patients’ testing reports, and were suspected of medical insurance fraud.

The NHSA and public security ministry held a meeting with company officials in December to brief them on the investigation, it added.

“AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS,” it said.

An AstraZeneca spokesperson said all employees involved in the Shenzhen case were Chinese nationals.

Comments

Comments are closed for this article.